Arlene E Garcia-Soto1, James J Java2, Wilberto Nieves Neira3, J Matthew Pearson4, David E Cohn5, Shashikant B Lele6, Krishnansu S Tewari7, Joan L Walker8, Angeles Alvarez Secord9, Deborah K Armstrong10, Larry J Copeland11. 1. Division of Gynecology Oncology, Department of OB-GYN, University of Miami Miller School of Medicine, Miami, FL, United States. Electronic address: Arlene_e_garcia@hotmail.com. 2. NRG Statistics and Data Management Center, Roswell Park Cancer Institute, Buffalo, NY, United States. Electronic address: james.j.java@gmail.com. 3. Division of Gynecology Oncology, Department of OB-GYN, University of Miami Miller School of Medicine, Miami, FL, United States. Electronic address: nwilberto@hotmail.com. 4. Division of Gynecology Oncology, Department of OB-GYN, University of Miami Miller School of Medicine, Miami, FL, United States. Electronic address: mpearson@med.miami.edu. 5. The Ohio State University, Columbus, OH, United States. Electronic address: David.Cohn@osumc.edu. 6. Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, United States. Electronic address: Shashi.Lele@RoswellPark.org. 7. Obstetrics-Gynecology, University of California, Irvine, Orange, CA, United States. Electronic address: ktewari@uci.edu. 8. Gynecologic Oncology, Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City, OK, United States. Electronic address: joan-walker@ouhsc.edu. 9. Gynecologic Oncology, Duke Medical Center, Durham, NC, United States. Electronic address: angeles.secord@duke.edu. 10. Gynecology and Obstetrics, Johns Hopkins Kimmel Cancer Center, Baltimore, MD, United States. Electronic address: ARMSTDE@jhmi.ed. 11. The Ohio State University, Columbus, OH, United States. Electronic address: larry.copeland@osumc.edu.
Abstract
OBJECTIVES: To determine the relationship of the time from surgery to intraperitoneal (IP) chemotherapy (TSIC) initiation with survival of patients with stage III epithelial ovarian cancer (EOC) patients using ancillary data from cooperative group clinical trials. METHODS: Data from 420 patients with stage III EOC treated with IP chemotherapy under GOG-0114 and 172 were reviewed. The Cox proportional hazards model was used to evaluate independent prognostic factors and estimate their covariate-adjusted effects on PFS and OS. RESULTS: The median TSIC was 62.5days (interquartile range 28-83). The median TSIC was longer for patients in GOG-0114 vs those in GOG-172 (83 vs 26days, p<0.001). TSIC was significantly associated (p=0.049) with PFS: each 10% increase in TSIC (days) decreases the risk of progression by 3%. TSIC was not significantly associated with OS in this model. In a linear regression model, gross residual disease was significantly associated with shorter TSIC (R2 -0.141, 95%CI -0.217, -0.064, p<0.001). When only data from GOG-172 were considered, no statistical significant association was found between TSIC and PFS or OS. CONCLUSIONS: In this ancillary data study, TSIC was not associated with improved OS in patients with stage III epithelial ovarian cancer. TSIC was significantly associated with PFS for the entire cohort, suggesting increase in PFS with longer TSIC. However, this was not found when only data from GOG 172 or GOG 114 were analyzed separately. Hence, the relationship between IP chemotherapy initiation and time from surgery needs to be studied further.
OBJECTIVES: To determine the relationship of the time from surgery to intraperitoneal (IP) chemotherapy (TSIC) initiation with survival of patients with stage III epithelial ovarian cancer (EOC) patients using ancillary data from cooperative group clinical trials. METHODS: Data from 420 patients with stage III EOC treated with IP chemotherapy under GOG-0114 and 172 were reviewed. The Cox proportional hazards model was used to evaluate independent prognostic factors and estimate their covariate-adjusted effects on PFS and OS. RESULTS: The median TSIC was 62.5days (interquartile range 28-83). The median TSIC was longer for patients in GOG-0114 vs those in GOG-172 (83 vs 26days, p<0.001). TSIC was significantly associated (p=0.049) with PFS: each 10% increase in TSIC (days) decreases the risk of progression by 3%. TSIC was not significantly associated with OS in this model. In a linear regression model, gross residual disease was significantly associated with shorter TSIC (R2 -0.141, 95%CI -0.217, -0.064, p<0.001). When only data from GOG-172 were considered, no statistical significant association was found between TSIC and PFS or OS. CONCLUSIONS: In this ancillary data study, TSIC was not associated with improved OS in patients with stage III epithelial ovarian cancer. TSIC was significantly associated with PFS for the entire cohort, suggesting increase in PFS with longer TSIC. However, this was not found when only data from GOG 172 or GOG 114 were analyzed separately. Hence, the relationship between IP chemotherapy initiation and time from surgery needs to be studied further.
Authors: Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger Journal: N Engl J Med Date: 2006-01-05 Impact factor: 91.245
Authors: Jason D Wright; Thomas J Herzog; Alfred I Neugut; William M Burke; Yu-Shiang Lu; Sharyn N Lewin; Dawn L Hershman Journal: Obstet Gynecol Date: 2012-10 Impact factor: 7.661
Authors: Dennis S Chi; Oliver Zivanovic; Kimberly L Levinson; Valentin Kolev; Jae Huh; Joseph Dottino; Ginger J Gardner; Mario M Leitao; Douglas A Levine; Yukio Sonoda; Nadeem R Abu-Rustum; Carol L Brown; Richard R Barakat Journal: Gynecol Oncol Date: 2010-07-06 Impact factor: 5.482
Authors: Dennis S Chi; Corinna C Franklin; Douglas A Levine; Faina Akselrod; Paul Sabbatini; William R Jarnagin; Ronald DeMatteo; Elizabeth A Poynor; Nadeem R Abu-Rustum; Richard R Barakat Journal: Gynecol Oncol Date: 2004-09 Impact factor: 5.482
Authors: Soo Young Jeong; Chel Hun Choi; Tae Joong Kim; Jeong Won Lee; Byoung-Gie Kim; Duk Soo Bae; Yoo-Young Lee Journal: J Ovarian Res Date: 2019-12-31 Impact factor: 4.234